Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments

Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital

March 1, 2017 6:35 AM EST

RBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $91.00 (from $98.00) while maintaining a Outperform rating amid conservative guidance.

Analyst Simos Simeonidis commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT... More

Sarepta Therapeutics (SRPT) Misses Q4 EPS by 29c, Sales Beat

February 28, 2017 4:46 PM EST

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.62), $0.29 worse than the analyst estimate of ($1.33). Revenue for the quarter came in at $5.42 million versus the consensus estimate of $4.72 million.

2016 was a transformative year, with the FDA accelerated approval of EXONDYS 51. In 2017, we are focused... More